SKU: CGL10≥ 99% HPLC
Cagri
Research Compound · Research use only

CagriCagri is a synthetic 39-amino acid acylated peptide analog classified as a dual amylin and calcitonin receptor agonist (DACRA), available as a lyophilized powder for laboratory research.

$86.99/ vial · 10mg
In stock
Est. Arrival: 11/25/2026Ships today if ordered by 4PM EST
Select Size
Volume Discounts
1
Purity
99%+
Form
Lypholized Powder
Quantity
10 mg
Storage
Store lyophilized at -20 °C, sealed, away from light and moisture
Batch / Lot
202612-01-CGL
99%+ PurityHPLC · third-party
COA Includedlot 202609-01-CGL
USA BasedMidwest Region
For Research Use Only. This product is intended for laboratory and scientific research purposes only. It is not a drug or dietary supplement and is not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease.
$86.99Cagri · 10mg × 1

Product Details

Cagri is a synthetic, acylated 39-amino acid peptide modified with a C20 di-acid fatty acid side chain for enhanced albumin binding. Features a disulfide bridge between Cys3 and Cys8 for structural stability.


Classified as a Dual Amylin and Calcitonin Receptor Agonist (DACRA). Store at -20°C protected from light.


Disclaimer: For laboratory research purposes only.

Frequently Asked Questions About Cagri

Answers summarize published research and are provided for laboratory research purposes only.

Cagri is a synthetic 39-amino acid acylated peptide analog of amylin, the pancreatic hormone released alongside insulin. It is classified as a dual amylin and calcitonin receptor agonist, abbreviated DACRA. Cagri carries a C20 di-acid fatty acid side chain for albumin binding and a disulfide bridge between Cys3 and Cys8. Biotech Compounds supplies Cagri as a lyophilized powder for laboratory research.
Yes. Cagri has progressed through animal models into human clinical trials. Published phase 1 and phase 2 studies have evaluated Cagri as a once-weekly long-acting amylin analog, and later trials have studied it in combination with a GLP-1 receptor agonist. Cagri remains an investigational compound and has not been approved as a medicine in any market.
Cagri and Eloralintide are both long-acting acylated amylin analogs, but they differ in receptor selectivity and length. Cagri is a 39-amino acid dual amylin and calcitonin receptor agonist, meaning it activates both receptor families. Eloralintide is a 37-amino acid analog that research describes as a selective amylin receptor agonist with less calcitonin receptor activity. Researchers comparing selective and non-selective amylin signaling can study both.
Yes. Cagri from Biotech Compounds is supplied at 99 percent or greater purity and is third-party tested. A Certificate of Analysis is available on the Cagri product page so researchers can review identity and purity results before use. Each lot of Cagri is tested independently.
Cagri has a molecular weight of 4,409.01 g/mol and a molecular formula of C194H312N54O59S2. The two sulfur atoms come from the cysteine residues at positions 3 and 8 that form the disulfide bridge. Cagri is a 39-amino acid peptide, two residues longer than native human amylin, with the added mass largely coming from the C20 fatty di-acid side chain.

Purity, documented